Lewinsohn, DM;
Leonard, MK;
LoBue, PA;
Cohn, DL;
Daley, CL;
Desmond, E;
Keane, J;
Lewinsohn, DA;
Loeffler, AM;
Mazurek, GH;
O'Brien, RJ;
Pai, M;
Richeldi, L;
Salfinger, M;
Shinnick, TM;
Sterling, TR;
Warshauer, DM;
Woods, GL.
BACKGROUND: Individuals infected with Mycobacterium tuberculosis (Mtb) may develop symptoms and signs of disease (tuberculosis disease) or may have no clinical evidence of disease (latent tuberculosis infection [LTBI]). Tuberculosis disease is a leading cause of infectious disease morbidity and mortality...
The present guideline update aims to use the best available evidence on the treatment of drug-susceptible TB, as well as on interventions to ensure adequate patient care and support, in order to inform policy decisions made in these technical areas by national TB control programme managers, national poli...
Nahid, P;
Dorman, SE;
Alipanah, N;
Barry, PM;
Brozek, JL;
Cattamanchi, A;
Chaisson, LH;
Chaisson, RE;
Daley, CL;
Grzemska, M;
Higashi, JM;
Ho, CS;
Ho, CS;
Hopewell, PC;
Keshavjee, SA;
Lienhardt, C;
Menzies, R;
Merrifield, C;
Narita, M;
O'Brien, R;
Peloquin, CA;
Raftery, A;
Saukkonen, J;
Schaaf, HS;
Sotgiu, G;
Starke, JR;
Migliori, GB;
Vernon, A.
The American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America jointly sponsored the development of this guideline for the treatment of drug-susceptible tuberculosis, which is also endorsed by the European Respiratory Society and the US National Tube...
Ren, CL;
Esther CR, Jr;
Debley, JS;
Sockrider, M;
Yilmaz, O;
Amin, N;
Bazzy-Asaad, A;
Davis, SD;
Durand, M;
Ewig, JM;
Yuksel, H;
Lombardi, E;
Noah, TL;
Radford, P;
Ranganathan, S;
Teper, A;
Weinberger, M;
Brozek, J;
Wilson, KC.
"BACKGROUND:
Infantile wheezing is a common problem, but there are no guidelines for the evaluation of infants with recurrent or persistent wheezing that is not relieved or prevented by standard therapies.
METHODS:
An American Thoracic Society-sanctioned guideline development committee selected clinical...
In November 2015, the World Health Organization (WHO) convened a meeting of a Guideline Development Group (GDG) for the update of policy recommendations on the treatment of drug-resistant TB. The GDG was composed of a multidisciplinary group of tuberculosis (TB) and drug-resistant TB experts external to ...
Early detection of tuberculosis (TB) is essential to improve health outcomes for people with TB, and to reduce TB transmission more effectively. Systematic screening in high risk groups is a complement to efforts to improve the patient-initiated pathway to TB diagnosis (that is, diagnosing TB among peopl...
Tests based on the detection of mycobacterial lipoarabinomannan (LAM) antigen in urine have
emerged as potential point-of-care tests for tuberculosis (TB). LAM antigen is a lipopolysaccharide
present in mycobacterial cell walls, which is released from metabolically active or degenerating
bacterial cells ...
Early detection of tuberculosis (TB) is essential to improve health outcomes for people with TB, and to reduce TB transmission more effectively. Systematic screening in high risk groups is a complement to efforts to improve the patient-initiated pathway to TB diagnosis (that is, diagnosing TB among peopl...
In 2011 WHO conditionally recommended the use of at least 36 months of isoniazid preventive therapy (IPT) (as a proxy for lifelong or continuous treatment) for people living with HIV in high TB-prevalence and transmission settings. The evidence of the benefits and harms of 36-month IPT compared to 6-mont...
This Guideline outlines the purpose and the target audience of the second edition of Guidance for national tuberculosis programmes on the management of tuberculosis in children. It discusses the difference between TB in children and adolescents and TB in adults and provides an estimate of the burden of c...
